지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous
system (CNS) and one of the most common disabling neurological diseases of young
adults. Although the exact mechanisms involved in MS pathogenesis remain unclear, MS is
believed to be caused by interactions between as yet unidentified environmental factors and
susceptibility genes. Symptoms commonly occurred in MS include visual disturbance; weakness;
spasticity; sensory disturbances; ataxia; bladder, bowel, and sexual dysfunction; fatigue; affective
symptoms; and cognitive impairment. Most patients initially undergo a relapsing-remitting course,
however, without treatment, the majority of them make a transition to the secondary progressive
form. The clinical diagnosis is based on demonstrating neurological lesions, predominantly in the
white matter, that are disseminated over space with the lapse of time. The key to the successful
MS management is to prevent disability. Although there is no effective cure for MS, therapies are
available that mitigate the course of the disease, treat relapses and improve symptoms, all of
which place a significant impact on patients’ quality of life. Recent clinical trials suggest that early
identification and treatment are critical to optimize the treatment benefit. Currently six agents have
been specifically approved for mitigating the course of MS. These include three formulations of
interferon beta, glatiramer acetate, mitoxantrone, and natalizumab. Recent advances in understanding
of immune pathogenesis lead us to new therapeutic approaches focused on precise target
mechanisms. Many ongoing clinical trials will provide better treatment protocols in near future.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청이 논문의 저자 정보
최근 본 자료
댓글(0)
0